首页> 美国卫生研究院文献>Gels >A Controlled Antibiotic Release System for the Development of Single-Application Otitis Externa Therapeutics
【2h】

A Controlled Antibiotic Release System for the Development of Single-Application Otitis Externa Therapeutics

机译:用于单一应用性中耳炎治疗药物开发的可控抗生素释放系统

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Ear infections are a commonly-occurring problem that can affect people of all ages. Treatment of these pathologies usually includes the administration of topical or systemic antibiotics, depending on the location of the infection. In this context, we sought to address the feasibility of a single-application slow-releasing therapeutic formulation of an antibiotic for the treatment of otitis externa. Thixotropic hydrogels, which are gels under static conditions but liquefy when shaken, were tested for their ability to act as drug controlled release systems and inhibit Pseudomonas aeruginosa and Staphylococcus aureus, the predominant bacterial strains associated with outer ear infections. Our overall proof of concept, including in vitro evaluations reflective of therapeutic ease of administration, formulation stability, cytocompatibility assessment, antibacterial efficacy, and formulation lifespan, indicate that these thixotropic materials have strong potential for development as otic treatment products.
机译:耳部感染是一个普遍存在的问题,可能会影响各个年龄段的人。这些病理的治疗通常包括局部或全身使用抗生素,具体取决于感染部位。在这种情况下,我们试图解决一次性应用抗生素缓释治疗剂治疗外耳道炎的可行性。触变水凝胶是在静态条件下形成的凝胶,但在摇动时会液化,它们被用作药物控释系统并抑制铜绿假单胞菌和金黄色葡萄球菌(与外耳感染有关的主要细菌菌株)的能力。我们的总体概念证明,包括反映出治疗的易用性,制剂稳定性,细胞相容性评估,抗菌功效和制剂寿命的体外评估,表明这些触变材料具有作为耳处理产品开发的强大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号